Algen Biotechnologies

algenbio.com →

0%

est. 2Y upside i

HealthcareSeries D+

Using CRISPR to find treatments for cancer and inflammation

Rank

#2933

Sector

Biotechnology

Est. Liquidity

~4Y

Data Quality

Data: Low

Due to missing financial data (valuation, revenue), a quantitative equity upside analysis is not possible.

Last updated: July 3, 2026

Bull (10%)0%

Bull case requires successful pipeline progress and IPO window, but without valuation data upside cannot be quantified.

Base (50%)0%

Base case assumes gradual progress, but missing financial data precludes numerical projection.

Bear (40%)0%

Bear case: high incumbent threat and early stage may lead to failure; common stock could be worthless.

Est. time to liquidity~4.0 years

Preference Stack Risk

high

Funding Intensity

0%

Total funding $18M; valuation unknown but likely moderate to high preference overhang.

Dilution Risk

high

With $18M total funding and 15 employees, likely need additional capital within 2 years, causing dilution.

Secondary Liquidity

none

No secondary market data available.

Questions to Ask at the Interview

Strategic questions based on Algen Biotechnologies's data — designed to show you've done your homework.

  • 1

    “How does AlgenBrain differentiate from Isomorphic Labs' approach?”

  • 2

    “What is the company's current burn rate and runway?”

  • 3

    “What milestones are expected in the next 2 years?”

Community

Valuation Sentiment

Our model estimates 0% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.